Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2020-03-12. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cellcancerbreastchronicchemotherapy
  Phrases that lowered it: arthritisrheumatoidevaluate theto evaluateupper
• Sponsor's past termination rate: 18.2% (raises risk) · Sponsor's track record
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 126 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 302 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Disease area, dermatology: Yes (raises risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse NCT02364492 · started 2015 · scored riskier than 47% of active trials completed
• Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy NCT03199040 · started 2019 · scored riskier than 73% of active trials terminated
• Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer NCT00807781 · started 2009 · scored riskier than 93% of active trials completed
• Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer NCT01532960 · started 2012 · scored riskier than 93% of active trials terminated
• Vaccination of High Risk Breast Cancer Patients NCT02229084 · started 2015 · scored riskier than 98% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.